30
Participants
Start Date
April 1, 2019
Primary Completion Date
March 30, 2020
Study Completion Date
March 31, 2021
Typhoid Vi Polysaccharide Vaccine
Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
Placebo
The placebo injection will consist of 0.5mL of saline.
San Francisco Veterans Affairs Medical Center, San Francisco
University of California, San Francisco, San Francisco
National Institute of Mental Health (NIMH)
NIH
University of California, San Francisco
OTHER